Methylpiperazine

Methylpiperazine

SCHEMBL6444755

CN1CCNCC1.CS(=O)(=O)c1nc(N)nc(-c2ccco2)c1C#N

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.48
ADORA1 P30542 12/20 0.48
ADORA2B P29275 5/20 0.48
ERAP1 Q9NZ08 1/20 0.46
HRH1 P35367 2/20 0.38
HRH4 Q9H3N8 2/20 0.38
HRH3 Q9Y5N1 2/20 0.38
KCNH2 Q12809 1/20 0.38
ADORA3 P0DMS8 2/20 0.38
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HIF1A Q16665 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CASP1 P29466 1/20 0.36
BLM P54132 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441044 0.87 ADORA2A (0.61) ADORA2AADORA1ADORA2BADORA3ALDH1A1
SCHEMBL7406893 0.75 ADORA1 (0.46) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6448539 0.75 ADORA2A (0.56) ADORA2AADORA1ADORA2BERAP1HRH1
SCHEMBL6441983 0.71 ADORA2A (0.51) ADORA2AADORA1ADORA2BERAP1HRH1
SCHEMBL6440893 0.70 ADORA2A (0.68) ADORA2AADORA1ADORA2BADORA3ALDH1A1
SCHEMBL6441202 0.69 ADORA2A (0.72) ADORA2AADORA1ADORA2BADORA3ALDH1A1
SCHEMBL6442665 0.69 ADORA1 (0.67) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL5041600 0.68 ADORA2A (0.70) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL5036770 0.68 ADORA2A (0.58) ADORA2AADORA1ADORA2BERAP1HRH1
SCHEMBL6446123 0.68 ADORA2A (0.65) ADORA2AADORA1ADORA2BALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.